NRAS and melanoma: In the overall melanoma cohort (n = 1268), GA were present in TERTp (65.9%, 835), TP53 (23.9%, 303), CDKN2A (44.7%, 567), BRAF (41.0%, 520), NRAS (22.6%, 287), CTNNB1 (4.7%, 60), PRKAR1A (0.9%, 11), GNAQ (3.5%, 45), GNA11 (2.7%, 34), KIT (5.8%, 74), PTEN (15.3%, 194), and BAP1 (4.7%, 59).